为什么要测试痴呆症:患者的观点,重要的人和全科医生
Iris Linden1, Claire Wolfs1, Maud Hevink1
1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Alzheimer Centre Limburg, Maastricht University, Maastricht, The Netherlands.
Age and ageing
|January 22, 2024
概括
了解痴呆症诊断测试决策需要探索患者和GP的观点. 共享决策至关重要,但往往缺乏,强调需要更好的患者参与辅助工具.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 痴呆症诊断测试决策涉及患者,他们的家人和全科医生.
- 了解利益相关者的期望,需求和经验是改善这一过程的关键.
研究的目的:
- 了解痴呆症诊断测试的决策过程.
- 探索患有记忆障碍的患者,他们的亲朋好友和全科医生的观点.
主要方法:
- 与患者 (年龄>60岁),他们的重要其他人和全科医生进行了半结构化采访.
- 使用面试成绩单的主题分析,直到数据和.
- 包括51次采访:20名患者,15名重要他人和16名全科医生.
主要成果:
- 确定了关键主题:测试的驱动因素,影响决策的患者偏好,需要个性化沟通,以及共同决策 (SDM) 的障碍.
- 患者通常对诊断选择的认识有限,尽管全科医生重视SDM.
- 决策过程是多因素的,以个人偏好为指导.
结论:
- 痴呆症诊断测试的决定是复杂的,取决于偏好,但往往缺乏明确的联合决策.
- 开发患者决策辅助工具可以提高患者的参与度,并促进更明智的选择.
相关概念视频
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


